Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share

Board of Directors of Revance Recommend Stockholders Tender their Shares JOHNSON CITY, Tenn., Dec. 12, 2024 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash tender offer to acquire all outstanding shares of common stock of Revance Therapeutics, Inc., ("Revance") (Nasdaq: RVNC) at a price of $3.10 per share in cash. The tender offer is being made in connection with the Amended and Restated Mer ...